Glenmark Pharma Rises Nearly 1% as US Arm Set to Launch Ropivacaine Hydrochloride Injection

Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials

ELMWOOD PARK, N.J., Oct. 24, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL)…

Glenmark Pharmaceuticals to Launch Ropivacaine Hydrochloride Injection USP in the United States

Glenmark Pharmaceuticals has announced the upcoming lau […] The post Glenmark Pharmaceuticals to Launch Ropivacaine Hydrochloride Injection USP in the United States first appeared on GeneOnline News. The post Glenmark Pharmaceuticals to Launch Ropivacaine Hydrochloride Injection USP in the United States appeared first on GeneOnline News.

Glenmark to launch Ropivacaine Hydrochloride Injection USP in the US

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Ropivacaine Hydrochloride Injection USP in three single-dose vial strengths: 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL). Distribution is scheduled to begin in November 2025. Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin® Injection, 40 mg/20 mL (2 …

Glenmark Pharma Rises Nearly 1% as US Arm Set to Launch Ropivacaine Hydrochloride Injection

Mumbai, October 23 (Udaipur Kiran) — Shares of Glenmark Pharmaceuticals gained nearly 1% in Thursday’s trading session after the company announced that its US-based subsidiary is preparing to launch Ropivacaine Hydrochloride Injection USP in multiple dosage strengths. The stock was trading at ₹1,873.20, up by ₹17.50 or 0.94%, from its previous close of ₹1,855.70 on the BSE. It opened at ₹1,870.00 and touched an intraday high of ₹1,878.00 and a l…